Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday ...

In a merger between two subcutaneous drug delivery companies, Halozyme Therapeutics is paying $750 million in cash to acquire Elektrofi. Aside from the $750 million upfront payment, the deal also ...

U.S. company Halozyme Therapeutics, regarded as a competitor to Korea's bio corporations Alteogen, will acquire Elektrofi, which has subcutaneous injection drug delivery technology, for up to $900 ...

SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it has entered into a definitive agreement to acquire Elektrofi, Inc. ("Elektrofi"), a ...

Halozyme's acquisition of Elektrofi includes the innovative Hypercon technology, enabling ultra-high concentration biologic formulations for improved drug delivery. The acquisition supports Halozyme's ...

Halozyme Therapeutics has been busy. While fighting a patent dispute with Merck & Co. and navigating the impact of the Inflation Reduction Act (IRA), the company has penned an acquisition of fellow ...

SAN DIEGO, Nov. 25, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host ...